GENERIC-DRUG USE FIGURES TO RISE SHARPLY IN EUROPE

SEPTEMBER 01, 2007

The appetite for generic drugs throughout the European Community is expected to double in the next 7 years, jumping from $17.18 billion in 2006 to nearly $36 billion by 2013, according to a new market analysis by Frost & Sullivan. As in the United States, rising health costs in Europe are causing government leaders to explore methods for promoting increased use of more cost-effective generic medicines, the study noted.

?Patent expiries, pro-generic reforms in certain countries, and need for cheap, effective medicines are the key factors driving growth in the European generics market,? a researcher for the company explained. ?Various studies have indicated the cost savings obtained from generics, and several governments in Europe are actively promoting generics.?



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.